Posaconazole salvage treatment in paediatric patients: A multicentre survey

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 29, Issue 8, 2010, Pages 1043-1045

  Lehrnbecher, T ^a   Attarbaschi, A ^b   Duerken, M ^c   Garbino, J ^d   Gruhn, B ^e   Kontny, U ^f   Luer S ^g   Phillips, R ^h   Scholz, J ⁱ   Wagner, H J ^j   Wiesel, T ^k   Groll, A H ^l  

^a GOETHE UNIVERSITY   (Germany)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

^c Department of Dermatology   (Germany)

^d Geneva Children's Hospital   (Switzerland)

^e FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

^g Department of Orthopaedic Surgery   (Switzerland)

^h Children's Hospital of Leeds   (United Kingdom)

ⁱ SANOFI   (France)

^j UNIVERSITY HOSPITAL GIESSEN   (Germany)

^k Children's Hospital of Datteln   (Germany)

^l Children's Hospital of Münster   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; POSACONAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; NAUSEA; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SCHOOL CHILD; SYSTEMIC MYCOSIS; UNSPECIFIED SIDE EFFECT; VOMITING; ZYGOMYCOSIS; CLINICAL TRIAL; MULTICENTER STUDY; MYCOSES; PROCEDURES; TIME; TREATMENT OUTCOME;

ADOLESCENT; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MYCOSES; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 77955467469     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-010-0957-4     Document Type: Article

References (10)

1. B De Pauw TJ Walsh JP Donnelly DA Stevens JE Edwards T Calandra PG Pappas J Maertens O Lortholary CA Kauffman DW Denning TF Patterson G Maschmeyer J Bille WE Dismukes R Herbrecht WW Hope CC Kibbler BJ Kullberg KA Marr P Munoz FC Odds JR Perfect A Restrepo M Ruhnke BH Segal JD Sobel TC Sorrell C Viscoli JR Wingard T Zaoutis JE Bennett 2008 Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group Clin Infect Dis 46 1813 1821 10.1086/588660 18462102
2. J Maertens I Raad G Petrikkos M Boogaerts D Selleslag FB Petersen CA Sable NA Kartsonis A Ngai A Taylor TF Patterson DW Denning TJ Walsh 2004 Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy Clin Infect Dis 39 1563 1571 10.1086/423381 1:CAS:528:DC%2BD2cXhtFGgtr3I 15578352 (Pubitemid 39578526)
3. National Cancer Institution (NCI) Common Toxicity Criteria version 3.0 (2006) Common terminology criteria for adverse events v3.0 (CTCAE). Available at http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf. Accessed October 12, 2009.
4. OA Cornely J Maertens DJ Winston J Perfect AJ Ullmann TJ Walsh D Helfgott J Holowiecki D Stockelberg YT Goh M Petrini C Hardalo R Suresh D Angulo-Gonzalez 2007 Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia N Engl J Med 356 348 359 10.1056/NEJMoa061094 1:CAS:528:DC%2BD2sXhtVGrsrw%3D 17251531 (Pubitemid 46148777)
5. S Langner PB Staber P Neumeister 2008 Posaconazole in the management of refractory invasive fungal infections Ther Clin Risk Manag 4 747 758 1:CAS:528:DC%2BD1cXht1ShurvI 19209257
6. AJ Ullmann JH Lipton DH Vesole P Chandrasekar A Langston SR Tarantolo H Greinix W Morais de Azevedo V Reddy N Boparai L Pedicone H Patino S Durrant 2007 Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease N Engl J Med 356 335 347 10.1056/NEJMoa061098 1:CAS:528:DC%2BD2sXhtVGktb4%3D 17251530 (Pubitemid 46148776)
7. RN Greenberg K Mullane JA van Burik I Raad MJ Abzug G Anstead R Herbrecht A Langston KA Marr G Schiller M Schuster JR Wingard CE Gonzalez SG Revankar G Corcoran RJ Kryscio R Hare 2006 Posaconazole as salvage therapy for zygomycosis Antimicrob Agents Chemother 50 126 133 10.1128/AAC.50.1.126-133.2006 1:CAS:528:DC%2BD28XivVGltA%3D%3D 16377677 (Pubitemid 43042912)
8. II Raad HA Hanna M Boktour Y Jiang HA Torres C Afif DP Kontoyiannis RY Hachem 2008 Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin Leukemia 22 496 503 10.1038/sj.leu.2405065 1:CAS:528: DC%2BD1cXjt1Ggurc%3D 18094720 (Pubitemid 351395097)
9. JA van Burik RS Hare HF Solomon ML Corrado DP Kontoyiannis 2006 Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases Clin Infect Dis 42 e61 e65 10.1086/500212 16511748
10. TJ Walsh I Raad TF Patterson P Chandrasekar GR Donowitz R Graybill RE Greene R Hachem S Hadley R Herbrecht A Langston A Louie P Ribaud BH Segal DA Stevens JA van Burik CS White G Corcoran J Gogate G Krishna L Pedicone C Hardalo JR Perfect 2007 Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial Clin Infect Dis 44 2 12 10.1086/508774 1:CAS:528:DC%2BD2sXnvVCjtg%3D%3D 17143808 (Pubitemid 44968977)